RINVOQ® (upadacitinib) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.1
RINVOQ achieved the primary endpoints of clinical remission per adapted Mayo score at Induction Week 8 and Maintenance Week 521,2
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
[Note to Affiliate: HCP-delivered patient materials and their inclusion herein are subject to local codes and regulations.]
Watch this Introduction to RINVOQ video, for patients prescribed RINVOQ. This video is supplementary to the Patient Information Leaflet.
< Affiliate to link to locally approved project ALL-RNQG-XXXXXX >
Hear a rheumatologist and a dermatologist discuss their experiences using RINVOQ with their patients.
< Affiliate to link to locally approved project ALL-RNQG-220027 >
[AFFILIATES TO INSERT CONTENT AS APPLICABLE PER LOCAL CODES AND REGULATIONS AND MRLO APPROVALS]
This guide has been designed to help your patients who have been prescribed RINVOQ, to navigate their treatment journey step-by-step.
Printed Materials
For patients who prefer not to receive information digitally, all items are available as hard copy materials.
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
To receive printed versions of any of these materials for your patients, submit your details on the Contact Us page.
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
Read more about the RINVOQ Phase 3 clinical trial program for ulcerative colitis here
[Affiliate to insert PubMed link to Danese manuscript, if applicable]
RINVOQ is an oral, once-daily, selective and reversible JAK inhibitor now approved for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were tolerant to either conventional therapy or a biologic agent.1
RINVOQ can be taken at any time of the day, with or without food. Tablets should be swallowed whole and should not be split, crushed, or chewed in order to ensure the entire dose is delivered correctly.1
A Phase 3 clinical trial program involving 3 studies: 2 replicate induction studies and 1 maintenance study evaluated RINVOQ 45 mg QD vs placebo for induction and RINVOQ 15 mg QD and 30 mg QD vs placebo for maintenance treatment.1,2
Learn more about RINVOQ in our quick introductory video.
< Affiliate to link to locally approved project ALL-RNQG-220006 >
aMs: adapted Mayo score; ESS: endoscopic subscore; JAK: Janus kinase; QD: once daily; RBS: rectal bleeding score; UC: ulcerative colitis.
Study designs: U-ACHIEVE Induction (UC-1) and U-ACCOMPLISH (UC-2) were replicate induction studies, both of which were multicenter, double-blind, placebo-controlled clinical studies. In UC-1 and UC-2, 988 patients (473 and 515 patients, respectively) were randomized to RINVOQ 45 mg QD or placebo for 8 weeks with a 2:1 treatment allocation ratio and included in the efficacy analysis. All enrolled patients had moderately to severely active UC defined as aMs of 5 to 9 with an ESS of 2 or 3 and demonstrated prior treatment failure including inadequate response, loss of response, or intolerance to prior conventional and/or biologic treatment. U-ACHIEVE Maintenance (UC-3) was a multicenter, double-blind, placebo-controlled clinical study with 451 patients who achieved clinical response per aMs (decrease ≥2 points and ≥30% from baseline and a decrease in RBS ≥1 from baseline or an absolute RBS ≤1) with 8-week RINVOQ 45 mg QD induction treatment. Patients were rerandomized 1:1:1 to receive either RINVOQ 15 mg QD, 30 mg QD, or placebo.1,2
[Please insert local summary of safety]
REFERENCES
- RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG; December 2023.
- Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. doi:10.1016/S0140-6736(22)00581-5
I want to find out more about RINVOQ
I want to receive more information about RINVOQ
[Affiliates to insert local adverse events reporting websites]
ALL-RNQG-220224 Date of preparation: February 2024
Adverse events should also be reported to AbbVie on GBPV@abbvie.com